NCCN Guidelines and Treatment Insights for Desmoid Tumors

EP: 1.Desmoid Tumors: Characteristics and Diagnosis Challenges

EP: 2.ICD-10 Impact: Desmoid Tumor Advances

EP: 3.Imaging and Risks in Desmoid Tumors

EP: 4.Gene Expression in Desmoid Treatment

EP: 5.Multidisciplinary Care for Desmoid Tumors

Now Viewing

EP: 6.NCCN Guidelines and Treatment Insights for Desmoid Tumors

EP: 7.Desmoid Tumor Treatment: Bridging Gaps Between Community and Academic Care

EP: 8.Strategic Desmoid Tumor Education and Access

EP: 9.Therapeutic Access and Emerging Treatments

EP: 10.Desmoid Tumors: Impact and Quality of Life

EP: 11.Managing Desmoid Tumor Challenges

EP: 12.Psychosocial Impact and Pain Management for Desmoid Tumors

EP: 13.Watchful Management and Patient Support for Desmoid Tumors

EP: 14.Empowering Desmoid Tumor Patients: Education and Resources

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tony Phillip, MD; Mrinal Gounder, MD; Ravin Ratan, MD, MEd; and Derek Van Amerongen, MD, MS.

Haumschild delves into the current standards of care and treatment landscape for desmoid tumors, referencing the National Comprehensive Cancer Network (NCCN) guidelines. Ratan emphasizes the guidelines’ strategic division of tumors into those at risk of complications and those not, promoting active surveillance for the majority. The guidelines avoid overprescription, reflecting the need for tailored, multidisciplinary approaches. Van Amerongen highlights the significance of NCCN guidelines as a gold standard, guiding health plan policies to align with the latest treatment algorithms.

Gounder details the current standard of care, emphasizing a shift from surgery to up-front watchful waiting. Individualized decision-making considers patient symptoms, tumor progression, and location. Local approaches, including high-intensity focused ultrasound and transarterial chemoembolization, complement systemic therapies such as traditional cytotoxic chemotherapies, tyrosine kinase inhibitors, and γ-secretase inhibitors. Clinical trials remain crucial for exploring novel options, ensuring optimal care for rare diseases such as desmoid tumors. The discussion underscores the importance of aligning treatment decisions with NCCN guidelines, providing valuable insights for both providers and payers in managing desmoid tumors effectively.

Video synopsis is AI generated and reviewed by AJMC^® editorial staff.